Furthermore, when we compared the impacts of Prmt1, Ripk1 or Axl inhibition on the expression of DEGs in pre-treated tumor samples between responders and non-responders to ACT and ICB, our results showed that perturbing these factors tends to modify tumor transcriptional profiles towards the profiles favoring antitumor immune responses. The gene discussed is RIPK1; the disease is neoplasm.